Ignite Creation Date:
2024-05-06 @ 7:09 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05918692
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2023-05-18
Brief Title:
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
Sponsor:
Biomea Fusion Inc
Organization:
Biomea Fusion Inc
Study Overview
Official Title:
A Phase 1 Open-label Dose-escalation and Dose-expansion Study of BMF-500 an Oral Covalent FLT3 Inhibitor in Adults With Acute Leukemia
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500 an oral FLT3 inhibitor in adult patients with acute leukemia
Detailed Description:
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500 an oral covalent FLT3 inhibitor in adult patients with acute myeloid leukemia AML acute lymphocytic leukemia ALL and Acute Mixed-Phenotype Leukemia MPAL who may or may not be on Antifungals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None